RE:RE:RE:RE:RE:Lift off!!!From Aprilgoup:
"ONCY has some nice studies but they are with tiny patient populations and they are showing only small incremental improvements in disease outcomes. In an area with unmet needs this is significant but big pharma is unlikely to spend multi billions on this until more questions are answered.
This statement is wrong on two counts. First, the target patient populations are huge. The samples are not huge, but the FDA has signaled to ONCY in writing that smaller samples are acceptable with a biomarker. Second the results do not show small incremental improvements. The Goblet results show stunning improvements.
Yes, biotech is in a bear market. But so is the whole market.
Can you find other opportunities you think are better? Please sell here and go buy those.
I do not know how many times I have heard...."A biotech investor said ONCY is not so good, has its draw backs etc." No alternative treatments are better, that is for sure. Plus everyone who writes about this stock ignores the safety side, when virtually all other non-I/O treatments for cancer are toxic poison or have very limited applicability.
April gets ignored......